Sex: F
Vaccine: COVID19, COVID19
Symptoms: SARS-CoV-2 test
Clinical narrative: testing positive for SARS-CoV-2; COVID-19; This is a literature report for the following literature source(s):   A 14-year-old female patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "genital ulceration" (unspecified if ongoing), notes: first having occurred several months previously following fever, headaches, and body aches.; "presented to the emergency department" (unspecified if ongoing); "severe vulvar pain" (unspecified if ongoing), notes: with 2 days; "ulceration" (unspecified if ongoing), notes: with 2 days; "fever" (unspecified if ongoing); "headaches" (unspecified if ongoing); "body aches" (unspecified if ongoing); "second episode of genital ulceration" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Clobetasol for genital ulceration, reaction(s): "She had no improvement", notes: 0.05 percent ointment twice daily; Lidocaine for genital ulceration, reaction(s): "She had no improvement", notes: 2 percent gel; Acetaminophen for genital ulceration, reaction(s): "She had no improvement", notes: oral; Ibuprofen for genital ulceration, reaction(s): "She had no improvement", notes: as needed; Nortriptyline for genital ulceration, reaction(s): "She had no improvement", notes: oral; Lidocaine for genital ulceration, notes: 5 percent ointment; Prednisone for genital ulceration, notes: oral; taper (20 mg twice daily for 5 days followed by 20 mg once daily for 5 days). The following information was reported: DRUG INEFFECTIVE (medically significant), outcome "unknown", described as "testing positive for SARS-CoV-2"; COVID-19 (medically significant), outcome "unknown". The patient underwent the following laboratory tests and procedures: Antineutrophil cytoplasmic antibody: normal or negative; normal or negative; normal or negative.; Antinuclear antibody: normal or negative; Blood immunoglobulin G: normal or negative; Complement factor: normal or negative.; Epstein-Barr virus antibody: negative; Epstein-Barr virus test: negative, notes: performed at the time of her first episode; Faecal calprotectin: negative or normal.; Herpes simplex test: negative, notes: performed at the time of her first episode; HLA marker study: negative or normal.; Ophthalmological examination: negative or normal.; Physical examination: was notable for left labial swelling and 2 ulcerat, notes: 2 ulcerations on the inner aspects of the left and right labia near the introitus; Rheumatoid factor: normal or negative; Rheumatological examination: normal or negative; SARS-CoV-2 test: negative, notes: performed at the time of her first episode; positive, notes: 6 months later.; Sender's Comments: Based on the information available  a possible contributory role of the suspect BNT162B2 cannot be excluded for the reported events of drug ineffective,covid-19.,Linked Report(s) : US-PFIZER INC-202200948342 Same article/drug/patient and different event;